{"entity":{"id":"nct03964727","kind":"trial","name":"Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors","aka":[],"tldr":"A phase 2 trial of Sacituzumab govitecan in advanced solid tumours, run by Gilead Sciences, active and no longer recruiting.","summary":"Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors is a phase 2 interventional study registered as NCT03964727 by Gilead Sciences, with 227 participants enrolled, started 2019-10-15 and due to reach its primary completion in 2025-01-15. Interventions recorded: Sacituzumab Govitecan-hziy. Results have been posted on the registry.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03964727","url":"https://clinicaltrials.gov/study/NCT03964727"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["sacituzumab-govitecan"],"companies":["gilead"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03964727","phase":"2","setting":"A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors","sponsor":"Gilead Sciences","enrolled":227,"outcomes":[]},"route":"/trials/nct03964727/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"company":[{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"}]}}